Abstract: 23 It is not currently possible to reliably visualise and track immune cells in the human central 
52
Equally, it has been shown in patients with rheumatoid arthritis and psoriatic arthritis that 53 joints with active arthritis selectively accumulate more ICG than joints from healthy patients, 54 when measured in the hands of patients and controls (3). Furthermore, ICG colocalised with 55 macrophages in the lipid-rich atheromas within 20 minutes of intravenous injection in an 56 experimental model in rabbits (4). This suggests that ICG could selectively accumulate 57 within macrophages and granulocytes.
58
Following intravenous ICG administration, the main peak of absorption is at a wavelength of 59 805 nm and the peak of fluorescence emission ranges from 820 to 835 nm, within the near 60 infrared spectrum (5). It is however well-recognised that the ICG absorption spectra and to a 61 lesser extent the emission spectra, can shift depending on concentration and the other 62 constituents in solution (6). ICG is injected as an intravenous bolus for ocular angiography 63 up to a maximum of 25 mg in usual practice and retinal images are typically only captured 64 over the first 30-minutes. This means that labelling of cells may not have been observed 65 previously in the human eye, as it is unlikely that cells will have had enough time to be 66 labelled with ICG or to infiltrate the eye if stained peripherally.
67
ICG is known to enhance the visibility of the retinal pigment epithelium (RPE) mosaic and 68 has been used in adaptive optics imaging (7, 8) . This staining has also been seen late after 69 administration in the normal rat retina (9) 128 Follow-up imaging was performed at a minimum of a further two timepoints of either 24 129 hours, 48 hours, 7 days, and 9 days post-ICG injection (Table S1) . Each subject received a 130 single injection of ICG at baseline only. No adverse events occurred during the study.
131
A peripheral blood sample of up to 10 mL was taken from the contralateral arm of that 132 injected with ICG at either 2-or 4-hours post-administration and at a later, broad range of 133 timepoints (24-or 48-hours, or 7-days post-administration) to maximise the chance of 134 detecting a positive signal, given the expected time to labelling was unknown. Where 135 possible following a study amendment, a pre-injection blood sample from the same 136 participant was also obtained for the first flow cytometric run for direct comparison pre-and 137 post-administration. For the second run (days later) fresh healthy donor blood was used as a 138 control, rather than storage and reuse of the participant's own blood, due to potential 139 depletion of subsets of immune cells as ICG-free blood was required to enable preparation 140 of a fluorescence-minus-one (FMO) control to assists with gating. Blood samples were 141 processed within 30 minutes of venepuncture for flow cytometry.
142
Retinal imaging platforms: 143 Retinal angiography and imaging were performed using two different devices: a Spectralis (11); Supplementary figure 1 ).
191
For antibody cocktail 2, live cells were gated-for as described above, and then CD14 + 
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Only one subject demonstrated ICG signal on peripheral blood immune cells using flow 240 cytometry. Angiography confirmed an acute choroidal neovascular membrane (CNV) which 241 had been symptomatic for five days prior to ICG injection (Figure 2A-D) . Discrete signals 242 around the CNV lesion were visible only in the near-infrared channel and were approximately 243 30 µm in diameter compatible with myeloid cells (Figure 2E-F 
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For a subset of participant blood samples, it was possible to measure activation markers using 276 flow cytometry (Figure 4, Supplementary Figures 2 and 3) . Aggregate data did not 277 demonstrate evidence of ICG resulting in an inflammatory or activated immunophenotype. As shown measuring CD62L on T-cells (p = 0.914; A), CD80 on monocytes (p = 0.914; B) , and 288 CD62L on granulocytes (p = 0.698; C). Each point is a single blood sample from 7 subjects.
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All activation markers underwent validation with positive control stimuli. Figure 2) . Measured from time of ICG injection. Timings were determined by participant availability and 460
following an amendment, extension to cover a range of longer intervals to maximise the 461 chance of signal detection. 
